A Phase II Dose-Response Study of Velcade and Bone Formation in Patients With Relapsed/Refractory Multiple Myeloma.

Trial Profile

A Phase II Dose-Response Study of Velcade and Bone Formation in Patients With Relapsed/Refractory Multiple Myeloma.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 14 Apr 2015

At a glance

  • Drugs Bortezomib (Primary)
  • Indications Multiple myeloma
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 05 Nov 2013 The extension trial has been discontinued due to low accrual and the departure of the lead investigator, according to the ClinicalTrials.gov record.
    • 05 Nov 2013 The extension trial has been discontinued due to low accrual and the departure of the lead investigator, according to the ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top